Get caught up quickly on the top news and calls moving stocks with these Top Fives, as compiled by the editors of The Fly.

1. STOCK NEWS:

Thermo Fisher (TMO) reiterated FY21 guidance and provided a better than expected view on FY22 [more]
Diamondback Energy (FANG) announced a $2B share repurchase program [more]
U.S. Steel (X) announced a site selection process for a new $3B mini mill [more]
AMC (AMC) CEO Adam Aron said he expects to accept ethereum ($ETH), bitcoin ($BTC), and litecoin ($LTC) as payment for tickets [more]
An FDA panel voted against recommending a booster dose of Pfizer's COVID vaccine for people 16 and older [more]

2. WALL STREET CALLS:

Take-Two (TTWO) downgraded to Market Perform from Outperform at BMO Capital [more]
Baird upgrades Accolade (ACCD) to Outperform on execution, valuation discount [more]
Jefferies downgrades Las Vegas Sands (LVS) on "growth uncertainty" in Macau [more]
Wynn Resorts (WYNN) downgraded to Hold from Buy at Argus [more]
Piper upgrades Five9 (FIVN) on potential for increased Zoom (ZM) takeover bid [more]

3. AROUND THE WEB:

Invesco (IVZ) is in talks over a potential merger with State Street's (STT) asset management unit, WSJ reports [more]
Zymeworks (ZYME) data "could intensify potential sale talks," Dealreporter says [more]
New Jersey will pull investments worth $182M from Unilever (UL) following subsidiary Ben & Jerry's decision to stop selling ice cream in Israeli-occupied territories, NY Times reports [more]
The Fed opposed the idea of Deutsche Bank (DB) buying Wells Fargo's (WFC) custody unit, Bloomberg reports [more]
Northern Oil (NOG) is the front-runner to acquire a stake in Comstock's (CRK) Bakken assets, Reuters says [more]

4. MOVERS:

Innate Pharma (IPHA) soars after announcing the results from the COAST Phase 2 trial of monalizumab conducted by AstraZeneca (AZN) [more]
BeiGene (BGNE) higher after announcing the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted an opinion recommending approval of Brukinsa for the treatment of adult patients with Waldenstrom's macroglobulinemia [more]
Protagonist Therapeutics (PTGX) drops after announcing the FDA has placed a clinical hold on the company’s rusfertide program [more]
TCR2 Therapeutics (TCRR) lower after announcing interim results from its Phase 1/2 trial of gavo-cel [more]
Gritstone bio (GRTS) falls after presenting updated results from the company’s Phase 1/2 GRANITE clinical trial and after announcing the dosing of the first patient in its Phase 2 SLATE clinical trial of [more]

5. EARNINGS/GUIDANCE:

INDEXES:

The Dow fell 166.44, or 0.48%, to 34,584.88, the Nasdaq lost 137.96, or 0.91%, to 15,043.97, and the S&P 500 declined 40.76, or 0.91%, to 4,432.99.